Top Markets
Coin of the day
Novan, Inc. Novan, Inc.

Novan, Inc.

NOVN
Rang in Aktien #39523
Novan, Inc. operates as a pre-commercial pharmaceutical entity specializing in... Novan, Inc. operates as a pre-commercial pharmaceutical entity specializing in nitric oxide-derived therapies for dermatological and anti-infective conditions. The company boasts a robust clinical-stage pipeline featuring several topical drug candidates. For skin-related ailments, these include SB204, a monotherapy aimed at acne vulgaris; SB206, an antiviral gel targeting viral skin infections; SB208, a broad-spectrum antifungal gel designed to combat various fungal skin and nail infections like athlete's foot; and SB414, a cream-based gel formulated for inflammatory skin diseases. Additionally, Novan is advancing SB207 to treat external genital warts, WH602 (an intravaginal gel) and WH504 (a non-gel formulation) both addressing high-risk human papillomavirus (HPV), and SB019, a candidate for SARS-CoV-2. The firm has cultivated strategic partnerships, holding a licensing agreement with Sato Pharmaceutical Co., Ltd., and engaging in a strategic alliance with Orion Corporation. Founded in 2006, Novan, Inc. maintains its headquarters in Durham, North Carolina.
Aktienkurs
$0.056
Zuletzt synchronisiert: 2023-08-21
Marktkapitalisierung
$451.38K
Veränderung (1 Tag)
8.74%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Novan, Inc. (NOVN)

Kategorie

Kursverlauf für Novan, Inc. (NOVN)
Höchster Schlusskurs: $0.05 am 2023-08-01

Niedrigster Schlusskurs: $209.16 am 2016-09-01
Kursverlauf der Aktie von Novan, Inc. von 2016 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2023 -95.77%
2022 -71.33%
2021 -31.07%
2020 -74.28%
2019 118.01%
2018 -74.35%
2017 -83.34%
2016 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$517.18 32.51%
US
$857.76 31.47%
NL
$733.78 7.43%
CH
$1.07K -6.40%
KR
$260.01 14.86%
BE